<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089166</url>
  </required_header>
  <id_info>
    <org_study_id>PK-07- 016</org_study_id>
    <nct_id>NCT01089166</nct_id>
  </id_info>
  <brief_title>Study to Compare the Bioavailability of Extended Release Metformin HCl Tablet Versus Glucophage XR® Tablets in Healthy Human Volunteers Under Fasting Condition</brief_title>
  <official_title>To Compare the Bioavailability of Extended Release Metformin HCl Tablet(Test Formulation, Torrent Pharmaceuticals Ltd.,India) Versus Glucophage XR® Tablets ( Reference Formulation, Bristol-Myers Squibb Company, USA) in Healthy Human Volunteers Under Fasting Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <brief_summary>
    <textblock>
      Objective: To compare the bioavailability of Extended Release Metformin HCl Tablet(Test
      formulation, Torrent Pharmaceuticals Ltd.,India) versus Glucophage XR® Tablets ( Reference
      formulation, Bristol-Myers Squibb Company, USA) in Healthy Human Volunteers under fasting
      condition.

      Study Design: An Open-Label, Randomised, 2-Period, 2-Treatment,Crossover Study under fasting
      condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>2</number_of_arms>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Torrent's Metformin tablets 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucophage XR® of Bristol- Myers Squibb Company, USA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Torrent's Metformin tablets 500 mg</arm_group_label>
    <arm_group_label>Glucophage XR® of Bristol- Myers Squibb Company, USA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must meet all of the following criteria in order to be included in the study:

               1. Sex: male.

               2. Age: 18 - 45 years.

               3. Subject with BMI of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight.

               4. Healthy and willing to participate in the study.

               5. Subject willing to adhere to the protocol requirements and to provide written
                  informed consent.

               6. Non-smokers or smoker who smokes less than 10 cigarettes a day.

        Exclusion Criteria:

          -  The subjects will be excluded from the study based on the following criteria:

               1. Clinically relevant abnormalities in the results of the laboratory screening
                  evaluation.

               2. Clinically significant abnormal ECG or Chest X-ray.

               3. Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg and diastolic
                  blood pressure less than 60 mm Hg or more than 90 mm Hg.

               4. Pulse rate less than 50/minute or more than 100/minute.

               5. Oral temperature less than 95°F or more than 98.6°F.

               6. Respiratory rate less than 12/minute or more than 20/minute

               7. Addiction to alcohol or history of any drug abuse within the past 2 years.

               8. Recent History of kidney or liver dysfunction.

               9. History of allergy to the test drug or any drug chemically similar to the drug
                  under investigation.

              10. Administration/ Intake of prescription or OTC medication for two weeks before the
                  study.

              11. Patients suffering from any chronic illness such as arthritis, asthma etc.

              12. HIV, HCV, HBsAg positive Subjects.

              13. Opioids, tetra hydrocannabinoids, amphetamine, barbiturates, benzodiazepine,
                  Cocaine positive Subjects based on urine test.

              14. Subjects suffering from any psychiatric (acute or chronic) illness requiring
                  medications.

              15. Administration of any investigational products in the period 0 to 3 months before
                  entry to the study.

              16. Intake of barbiturates or any enzyme-inducing drug in last three months.

              17. History of significant blood loss due to any reason, including blood donation in
                  the past 12 weeks. The total blood loss in last 3 months including for this study
                  will not exceed 350ml.

              18. History of any bleeding disorder.

              19. Existence of any surgical or medical condition, which, in the judgement of the
                  Chief investigator and/or clinical investigator, might interfere with the
                  absorption, distribution, metabolism or excretion of the drug or likely to
                  compromise the safety of Subjects.

              20. Inability to communicate or co-operate due to language problem, poor mental
                  development or impaired cerebral function.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jogesh mahajan, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Torrent Pharma Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Torrent Research Centre</name>
      <address>
        <city>Bhat</city>
        <state>Gujarat</state>
        <zip>382 428</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/</url>
  </link>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>June 18, 2010</last_update_submitted>
  <last_update_submitted_qc>June 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

